The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 365-372

  Myrick, Hugh ^a,b,c   Li, Xingbao ^b,c   Randall, Patrick K ^b   Henderson, Scott ^a,b   Voronin, Konstantin ^b   Anton, Raymond F ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Department of Psychiatry and Behavioral Sciences   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

alcoholism; aripiprazole; craving; neuroimaging

Indexed keywords

ARIPIPRAZOLE; PLACEBO; DOPAMINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; ASSOCIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; BRAIN; BRAIN MAPPING; DRUG EFFECTS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; YOUNG ADULT;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN MAPPING; CORPUS STRIATUM; CUES; DOPAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PIPERAZINES; QUINOLONES; YOUNG ADULT;

EID: 77955170774     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e75cff     Document Type: Article

References (72)

1. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. AVeterans Administration cooperative study. JAMA. 1986;256:1449-1455.
2. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
3. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
4. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36:544-552.
5. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
6. Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004;1003:9-17.
7. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology. 2002;27:248-259.
8. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
9. Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57:49-54.
10. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy. 2004;24:212-228.
11. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649-666.
12. Lindsey RL, Kaplan D, Koliatsos V, et al. Aripiprazole and extrapyramidal symptoms. J Am Acad Child Adolesc Psychiatry. 2003;42:1268-1269.
13. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol. 2005;25:363-366.
14. Lile JA, Stoops WW, Vansickel AR, et al. Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology. 2005;30:2103-2114.
15. Janiri L, Martinotti G, Di Nicola M. Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study. J Clin Psychopharmacol. 2007;27:519-520.
16. Warsi M, Sattar SP, Bhatia SC, et al. Aripiprazole reduces alcohol use. Can J Psychiatry. 2005;50:244.
17. Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28:5-12.
18. Martinotti G, Di Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23: 123-129.
19. Drobes DJ, Anton RF, Thomas SE, et al. A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology. 2003;28: 755-764.
20. Drobes DJ, Thomas SE. Assessing craving for alcohol. Alcohol Res Health. 1999;23:179-186.
21. O'Malley SS, Krishnan-Sarin S, Farren C, et al. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl). 2002;160:19-29.
22. Kranzler HR, Covault J, Pierucci-Lagha A, et al. Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res. 2008;32:573-579.
23. Voronin K, Randall P, Myrick H, et al. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigmVpossible influence of self-control. Alcohol Clin Exp Res. 2008;32:1954-1961.
24. Braus DF, Wrase J, Grusser S, et al. Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics. J Neural Transm. 2001;108:887-894.
25. George MS, Anton RF, Bloomer C, et al. Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues. Arch Gen Psychiatry. 2001;58:345-352.
26. Kareken DA, Sabri M, Radnovich AJ, et al. Olfactory system activation from sniffing: effects in piriform and orbitofrontal cortex. Neuroimage. 2004;22:456-465.
27. Myrick H, Anton RF, Li X, et al. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. 2004;29:393-402.
28. Schneider F, Habel U, Wagner M, et al. Subcortical correlates of craving in recently abstinent alcoholic patients. Am J Psychiatry. 2001;158:1075-1083.
29. Wrase J, Grusser SM, Klein S, et al. Development of alcohol-associated cues and cue-induced brain activation in alcoholics. Eur Psychiatry. 2002;17:287-291.
30. Myrick H, Anton RF, Li X, et al. Effect of naltrexone and ondansetron on alcohol cueYinduced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008;65: 466-475.
31. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 1995;38:95-137.
32. Katner SN, Weiss F. Neurochemical characteristics associated with ethanol preference in selected alcohol-preferring and-nonpreferring rats: a quantitative microdialysis study. Alcohol Clin Exp Res. 2001;25:198-205.
33. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci. 1992;654:171-191.
34. Melendez RI, Rodd-Henricks ZA, Engleman EA, et al. Microdialysis of dopamine in the nucleus accumbens of alcohol-preferring (P) rats during anticipation and operant self-administration of ethanol. Alcohol Clin Exp Res. 2002;26:318-325.
35. Wise RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev. 1989;13:129-133.
36. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-1 Clinical Version). Washington, DC: American Psychiatric Publishing, Inc; 1997.
37. Sobell LC, Sobell MB, Leo GI, et al. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988;83:393-402.
38. Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996;53:225-231.
39. Davis LJ, Jr, Hurt RD, Morse RM, et al. Discriminant analysis of the Self-administered Alcoholism Screening Test. Alcohol Clin Exp Res. 1987;11:269-273.
40. Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol. 1982;91:199-209.
41. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br J Addict. 1989;84:1353-1357.
42. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393:295-314.
43. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52-58.
44. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the Bshell[as compared with the Bcore[of the rat nucleus accumbens. Proc Natl Acad Sci USA. 1995;92:12304-12308.
45. Blomqvist O, Engel JA, Nissbrandt H, et al. The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur J Pharmacol. 1993;249:207-213.
46. Mocsary Z, Bradberry CW. Effect of ethanol on extracellular dopamine in nucleus accumbens: comparison between Lewis and Fischer 344 rat strains. Brain Res. 1996;706:194-198.
47. Weiss F, Lorang MT, Bloom FE, et al. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther. 1993;267: 250-258.
48. Weiss F, Mitchiner M, Bloom FE, et al. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology (Berl). 1990;101:178-186.
49. Yim HJ, Schallert T, Randall PK, et al. Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis. Alcohol Clin Exp Res. 1998;22:367-374.
50. Yoshimoto K, McBride WJ, Lumeng L, et al. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol. 1992;9:17-22.
51. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28:309-369.
52. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev. 1999;31:6-41.
53. Schultz W, Apicella P, Scarnati E, et al. Neuronal activity in monkey ventral striatum related to the expectation of reward. J Neurosci. 1992;12:4595-4610.
54. Middaugh LD, Szumlinski KK, Van Patten Y, et al. Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone. Alcohol Clin Exp Res. 2003;27:1892-1900.
55. Heinz A, Siessmeier T, Wrase J, et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry. 2005;162:1515-1520.
56. Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry. 2005;58:779-786.
57. Yoder KK, Kareken DA, Seyoum RA, et al. Dopamine D(2) receptor availability is associated with subjective responses to alcohol. Alcohol Clin Exp Res. 2005;29:965-970.
58. Knutson B, Adams CM, Fong GW, et al. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci. 2001;21:RC159.
59. Adcock RA, Thangavel A, Whitfield-Gabrieli S, et al. Reward-motivated learning: mesolimbic activation precedes memory formation. Neuron. 2006;50:507-517.
60. Schreckenberger M, Amberg R, Scheurich A, et al. Acute alcohol effects on neuronal and attentional processing: striatal reward system and inhibitory sensory interactions under acute ethanol challenge. Neuropsychopharmacology. 2004;29:1527-1537.
61. Wang GJ, Volkow ND, Franceschi D, et al. Regional brain metabolism during alcohol intoxication. Alcohol Clin Exp Res. 2000;24:822-829.
62. Gilman JM, Ramchandani VA, Davis MB, et al. Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J Neurosci. 2008;28:4583-4591.
63. Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18:10663-10671.
64. Carlsson C, Gullberg B. A double blind study with melperone and placebo in the treatment of chronic alcoholics. Int J Clin Pharmacol Biopharm. 1978;16:331-332.
65. Naranjo CA, Dongier M, Bremner KE. Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction. 1997;92:969-978.
66. Walter H, Ramskogler K, Semler B, et al. Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci. 2001;8:83-88.
67. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1- piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274:329-336.
68. Grant S, London ED, Newlin DB, et al. Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA. 1996;93:12040-12045.
69. Maas LC, Lukas SE, Kaufman MJ, et al. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry. 1998;155:124-126.
70. Wang GJ, Volkow ND, Fowler JS, et al. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci. 1999;64:775-784.
71. Breiter HC, Gollub RL, Weisskoff RM, et al. Acute effects of cocaine on human brain activity and emotion. Neuron. 1997;19:591-611.
72. Kilts CD, Schweitzer JB, Quinn CK, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001;58:334-341.